You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics and treatment response (actual response to Peg-interferon + ribavirin or expected response after addition of directly acting antivirals)

From: Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals

  Characteristics Catanzaro (HIV negative) Padua (HIV positive) Total
   n = 77 (74%) n = 27 (26%) n = 104 (100%)
Qualitative variables Gender:       
    Males (%) 37 (48) 6 (22) 43 (41)
    Females (%) 40 (52) 21 (78) 61 (59)
  Genotype:       
    1b (%) 60 (78) 16 (59) 76 (73)
    1a (%) 11 (14) 10 (37) 21 (20)
    1 (%) 6 (8) 1 (4) 7 (7)
  RVR with PEG-IFN/RBV:       
    nonSVR RVR (%) 2 (3) 0 (0) 2 (2)
    SVR RVR (%) 5 (6) 2 (8) 7 (7)
    SVR nonRVR (%) 41 (53) 9 (33) 50 (48)
    nonSVR nonRVR (%) 39 (38) 16 (59) 45 (43)
  Response to PEG-INF/RBV (actual):       
    SVR (%) 46 (60) 11 (41) 57 (55)
    Relapsers (%) 12 (15) 4 (15) 16 (15)
    Partials (%) 2 (3) 4 (15) 6 (6)
    Nulls (%) 17 (22) 8 (29) 25 (24)
  Response to PEG-INF/RBV + DAA in naïves (estimated):       
    SVR (%) 58 (75) 20 (75) 78 (75)
    Non response (%) 19 (25) 7 (25) 26 (25)
  Response to PEG-IFN/RBV in naïves plus PEG-IFN/RBV + DAA in non responders (estimated):       
    SVR (%) 62 (81) 19 (70) 81 (78)
    Non response (%) 15 (19) 8 (30) 23 (22)
Quantitative variables Age (at PEG-IFN/RBV start):    
    Median 50 45 47
    Range 20-70 36-60 20-70
    IQR 23 7 17
    Standard Deviation 14 5 12
  Duration of PEG-IFN/RBV treatment in weeks (actual):     
    Mean 44 40 42